Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLSTAR
2021-003151-41Phase 3Terminated
- Sponsor
- Servier
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing Futuximab/modotuximab + trifluridine/tipiracil with Trifluridine/tipiracil (2 arms). Started Sep 2021; status: terminated.
02
Drugs
futuximabmodotuximabtrifluridinetipiracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2021-003151-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003151-41.